SeekingAlphaOctober 20, 2026 at 7:21 AM NY7 Days Ago
IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution
IQVIA (IQV) earns a Buy rating on strong Q2 results and R&D bookings recovery. See growth drivers, AI upside, key risks, and $285â$305 target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha
